Indication: Pulmonary

Soluble tumor necrosis factor receptor; Enbrel (Etanercept) for the treatment of acute Non-infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) following Allogeneic Stem Cell Transplantation.

Sub-indication: Pulmonary

Drug Study

Principal Investigator: Alexandra Cheerva, M.D.
Norton Children's Cancer Institute, affiliated with the UofL School of Medicine

Sponsor: Children's Oncology Group (COG)

Search our entire site.